An unprecedented push to manufacture billions of doses this year alone has led to supply bottlenecks, putting firms such as Pfizer and AstraZeneca Plc in the firing line of angry government customers. Now the industry is taking heat for closely guarding its intellectual property.

The discovery of multiple safe and effective Covid-19 vaccines has been the reputational boost the pharmaceutical industry needed. As science has caught up to the coronavirus, the price-inflating antics of Martin Shkreli and manufacturers’ roles in the opioid epidemic have faded into the background while people literally raise their glass to drugmakers like Pfizer.

An unprecedented push to manufacture billions of doses this year alone has led to supply bottlenecks, putting firms such as Pfizer and AstraZeneca in the firing line of angry government customers. The potential adverse effects of sticking needles into people’s arms are dominating headlines, as seen with the halting of the Astra vaccine in Canada and Europe even as regulators insist the benefits outweigh the risks.

Now the industry is taking heat for closely guarding its intellectual property. That’s blamed for what the World Health Organization dubs a “catastrophic moral failure”: the immunization gap between the developing world and deep-pocketed rich countries, which have ordered enough doses to cover their populations several times over.

If vaccine makers were to waive exclusive rights to manufacture their product – an idea pushed by 58 countries at the World Trade Organization including India and South Africa – advocates say that supply would bloom and we would exit the pandemic quicker. The push for a “people’s vaccine,” backed by the likes of Bernie Sanders, is popular with three-quarters of British voters and almost two-thirds of French people polled by YouGov.

Unlike in past crises such as HIV/AIDS, cracking open the recipe for Covid vaccines, especially those from Pfizer and Moderna is only half the battle given the complexity of genetic technologies making their debut in this pandemic. Manufacturing is a challenge too, and there isn’t much time for trial and error.

We haven’t quashed this virus yet and letting the pharma industry’s pandemic halo crash to the floor won’t help get us there any faster. Finding constructive ways to keep the public’s romance with drugmakers last a little longer makes sense, even if it doesn’t make money.

Read more at:

More News
News · 01/07/2022

The amendment makes QR codes mandatory on every active pharmaceutical ingredient. The Amendment Rules will come into force from January 01, 2023.

European Green Deal
News · 01/07/2022

On June 22, 2022, the Commission adopted pioneering proposals to restore damaged ecosystems and bring nature back across Europe, from agricultural land and seas, to forests and urban environments. The Commission also proposes to reduce the use and risk of chemical pesticides by 50% by 2030.

Neoadjuvant Dostarlimab is a promising treatment option in locally advanced dMMR rectal cancer
News · 01/07/2022

According to New York Times, in a small clinical trial, 18 patients took a drug called Dostarlimab for around six months, and in the end, every one of them saw their tumours disappear.

Global recession? Not yet…
News · 02/06/2022

As the war in Ukraine and pandemic disruptions continue to wreak havoc on supply chains, stagflation is here to stay – marked by low growth and high inflation for at least the next 12 months.

The pandemic as well as the war in Ukraine have stifled supply of commodities and goods and upended efficient distribution through global supply chains, forcing up prices of everyday goods such as fuel and food.

Roche develops unique PCR tests to detect the monkeypox virus
News · 01/06/2022

Roche and its subsidiary TIB Molbiol have developed three unique LightMix® Modular Virus kits in response to recent monkeypox virus concerns. Multiple clusters of the monkeypox virus have been reported within the past two weeks in several European countries and North America, which are regions where the virus is not normally found.

Containers pile up in Shanghai port on China’s COVID lockdowns
News · 02/05/2022

The strictest COVID -19 lockdown in China since the pandemic began has resulted in container goods sitting at Shanghai’s port for nearly two weeks.

Could cyber-physical watermarks be the key to pill-level traceability?
News · 01/04/2022

New anti-counterfeit technology, called a cyber-physical watermark, leverages edible fluorescent silk to identify medications.

World economy faces supply hit as China battles Covid
News · 01/04/2022

The global economy — already struggling with war in Ukraine and the stagflation risks it’s fanning — is bracing for greater disruption as China scrambles to contain its worst outbreak of Covid-19 since the pandemic began.

Impact of Oil hitting a seven-year high on world economy
News · 02/03/2022

Oil prices surged past $100 (£74) a barrel to hit their highest level for more than seven years after Russia launched an invasion of Ukraine.